Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telaglenastat + Cabozantinib in Advanced/Metastatic RCC
NCT03428217Phase 2Completed
- Sponsor
- Calithera Biosciences
- Start
- Apr 2018
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 8
01
Overview
A Phase 2 trial of telaglenastat in renal cell carcinoma (RCC), sponsored by Calithera Biosciences. Started Apr 2018; status: completed.
02
Drugs
telaglenastat
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT03428217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03428217.